These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 2061713)

  • 1. Parvalbumin-immunoreactive neurons in the neocortex are resistant to degeneration in Alzheimer's disease.
    Hof PR; Cox K; Young WG; Celio MR; Rogers J; Morrison JH
    J Neuropathol Exp Neurol; 1991 Jul; 50(4):451-62. PubMed ID: 2061713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calretinin-immunoreactive neocortical interneurons are unaffected in Alzheimer's disease.
    Hof PR; Nimchinsky EA; Celio MR; Bouras C; Morrison JH
    Neurosci Lett; 1993 Apr; 152(1-2):145-8. PubMed ID: 8515868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative analysis of a vulnerable subset of pyramidal neurons in Alzheimer's disease: II. Primary and secondary visual cortex.
    Hof PR; Morrison JH
    J Comp Neurol; 1990 Nov; 301(1):55-64. PubMed ID: 1706358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative analysis of a vulnerable subset of pyramidal neurons in Alzheimer's disease: I. Superior frontal and inferior temporal cortex.
    Hof PR; Cox K; Morrison JH
    J Comp Neurol; 1990 Nov; 301(1):44-54. PubMed ID: 2127598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parvalbumin-immunoreactive dystrophic neurites and aberrant sprouts in the cerebral cortex of patients with Alzheimer's disease.
    Ferrer I; Zújar MJ; Rivera R; Soria M; Vidal A; Casas R
    Neurosci Lett; 1993 Aug; 158(2):163-6. PubMed ID: 8233090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chandelier cell axons identified by parvalbumin-immunoreactivity in the normal human temporal cortex and in Alzheimer's disease.
    Fonseca M; Soriano E; Ferrer I; Martinez A; Tuñon T
    Neuroscience; 1993 Aug; 55(4):1107-16. PubMed ID: 8232900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parvalbumin immunoreactive neurons in normal human temporal neocortex and in patients with Alzheimer's disease.
    Ferrer I; Soriano E; Tuñón T; Fonseca M; Guionnet N
    J Neurol Sci; 1991 Dec; 106(2):135-41. PubMed ID: 1802961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neocortical neuronal subpopulations labeled by a monoclonal antibody to calbindin exhibit differential vulnerability in Alzheimer's disease.
    Hof PR; Morrison JH
    Exp Neurol; 1991 Mar; 111(3):293-301. PubMed ID: 1999232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Caspase-3 cleaved spectrin colocalizes with neurofilament-immunoreactive neurons in Alzheimer's disease.
    Ayala-Grosso C; Tam J; Roy S; Xanthoudakis S; Da Costa D; Nicholson DW; Robertson GS
    Neuroscience; 2006 Aug; 141(2):863-874. PubMed ID: 16750894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential incorporation of processes derived from different classes of neurons into senile plaques in Alzheimer's disease.
    Adams LA; Munoz DG
    Acta Neuropathol; 1993; 86(4):365-70. PubMed ID: 8256587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parvalbumin-immunoreactive neurons in the human central nervous system are decreased in Alzheimer's disease.
    Satoh J; Tabira T; Sano M; Nakayama H; Tateishi J
    Acta Neuropathol; 1991; 81(4):388-95. PubMed ID: 2028743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative distribution of parvalbumin, calretinin, and calbindin D-28k immunoreactive neurons in the visual cortex of normal and Alzheimer cases.
    Leuba G; Kraftsik R; Saini K
    Exp Neurol; 1998 Aug; 152(2):278-91. PubMed ID: 9710527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Substance P-like immunoreactive neurons are depleted in Alzheimer's disease cerebral cortex.
    Quigley BJ; Kowall NW
    Neuroscience; 1991; 41(1):41-60. PubMed ID: 1711654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunostaining of calmodulin and aluminium in Alzheimer's disease-affected brains.
    Solomon B; Koppel R; Jossiphov J
    Brain Res Bull; 2001 May; 55(2):253-6. PubMed ID: 11470324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progressive degeneration of nonphosphorylated neurofilament protein-enriched pyramidal neurons predicts cognitive impairment in Alzheimer's disease: stereologic analysis of prefrontal cortex area 9.
    Bussière T; Giannakopoulos P; Bouras C; Perl DP; Morrison JH; Hof PR
    J Comp Neurol; 2003 Aug; 463(3):281-302. PubMed ID: 12820162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contingent vulnerability of entorhinal parvalbumin-containing neurons in Alzheimer's disease.
    Solodkin A; Veldhuizen SD; Van Hoesen GW
    J Neurosci; 1996 May; 16(10):3311-21. PubMed ID: 8627368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Densities of parvalbumin-immunoreactive neurons in non-malformed hippocampal sclerosis-temporal neocortex and in cortical dysplasias.
    Zamecnik J; Krsek P; Druga R; Marusic P; Benes V; Tichy M; Komarek V
    Brain Res Bull; 2006 Feb; 68(6):474-81. PubMed ID: 16459206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Morphological and quantitative analysis of cerebellar cortical cells in Alzheimer's disease.
    Stępień T; Wierzba-Bobrowicz T; Lewandowska E; Szpak G
    Folia Neuropathol; 2012; 50(3):250-60. PubMed ID: 23023339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytoplasmic cytochrome c immunolabelling in dystrophic neurites in Alzheimer's disease.
    Woodhouse A; Vickers JC; Dickson TC
    Acta Neuropathol; 2006 Oct; 112(4):429-37. PubMed ID: 16855832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of perineuronal net N-acetylgalactosamine in Alzheimer's disease.
    Baig S; Wilcock GK; Love S
    Acta Neuropathol; 2005 Oct; 110(4):393-401. PubMed ID: 16133543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.